disease progression

Measurements from smartphones and wearable devices like smartwatches can reliably provide clinically meaningful data to monitor multiple sclerosis (MS), a new study from Switzerland reports. While daily data from such devices did not prove sufficiently reliable in this small study, information generated weekly — across more than 45 different…

Treatment with the neuroprotective protein HB-EGF eased inflammation and promoted tissue recovery across various disease stages in a multiple sclerosis (MS) mouse model, recent research suggests. Researchers found that HB-EGF is produced by astrocytes, a type of nerve support cell, to ease acute inflammation early on, but this protective…

Health Canada has approved the commercial use of ETNA-MS, a software-based medical device that uses eye tracking to noninvasively measure disease severity in people with multiple sclerosis (MS). Short for Eye-Tracking Neurological Assessment for Multiple Sclerosis, ETNA-MS assesses disease severity based on a person’s eye movements. It’s intended for…

While regulatory T-cells (Tregs) are able to promote remyelination — the repair of the myelin sheath that’s damaged in multiple sclerosis (MS) — this ability declines significantly with age, a new study shows. Based on the findings, researchers have identified molecular targets that may boost the myelin-repairing features…

My adolescent years can be characterized by a series of naps, long-lasting migraines, always being sick, and never being able to donate blood, which my family and I never understood. My journey with multiple sclerosis (MS) started long before my diagnosis in 2016. Let me set the…

Desiree Lama graduates from the University of Texas at Austin. (Photos courtesy of Desiree Lama) Day 24 of 31 This is Desiree Lama’s story: My journey with relapsing-remitting multiple sclerosis (RRMS) began when I was only 14 years old. I can vividly recall the smells, sights (or lack…

In multiple sclerosis (MS), lesions — areas of abnormal tissue in the nervous system — start as a core of a few inflammatory immune cells, with inflammatory damage then spreading outward from these cells to form a lesion. That’s according to a new study from Sweden, in which researchers…

Kristin Hardy considers herself happy and healthy — absent 22 years with PPMS, of course. (Photos courtesy of Kristin Hardy) Day 22 of 31 This is Kristin Hardy’s story: In 2001, I started experiencing symptoms of what rapidly manifested as primary progressive multiple sclerosis (PPMS). Like a…

Hi! I’m new — not to having multiple sclerosis (MS), but to being a columnist. I’m a daughter, wife, mother of two young adults, dog mom, sister, aunt, friend, college professor, pharmacist, avid reader, nature lover, and an MS warrior. I was diagnosed with MS in 2014, although…

Cathy Chester has been living with MS symptoms for more than 40 years. (Photos courtesy of Cathy Chester) Day 17 of 31 This is Cathy Chester’s story: My story with multiple sclerosis (MS) started more than 40 years ago when a car accident left me with a concussion,…

Leigh Anne Nelson wears the jersey of her favorite team, the Kansas City Chiefs. (Photos by Brett Nelson) Day 15 of 31 This is Leigh Anne Nelson’s story: During my first experience with what I believe was an MS-related illness in 1996, I had numbness and loss…

Surjeet Kaur’s MS journey involves sacrifice, but also awareness and positivity. (Photos courtesy of Surjeet Kaur) Day 14 of 31 This is Surjeet Kaur’s story: It was an ordinary day in November 2012 when I woke up with a stiff neck. I tried to brush this off thinking I…

Alex Ramirez stands outside of his home. (Photos courtesy of Alex Ramirez) Day 13 of 31 This is Alex Ramirez’s story: In January 2018, I started to feel terrible in a way I can’t put into words. I went to the hospital, and after multiple MRIs, I was prescribed…

Antonio Perez walks with his cane in the summer of 2022, saying his illness wasn’t that bad during that time. (Photos courtesy of Antonio Perez) Day 7 of 31 This is Antonio Perez’s story: Perez enjoys a glass of red wine. Hello, my name is Antonio Perez and…

The presence of paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, may help identify people with multiple sclerosis (MS) who are more likely to have cognitive decline over time. That’s according to four-year data presented by Hannah Schwartz,…

The antihistamine clemastine accelerated disease progression by more than five times in some adults with progressive multiple sclerosis (MS) who received it in a Phase 1/2 trial, new data show. Joanna Kocot, PhD, a neuroscientist at the National Institutes of Health (NIH), showed that this effect is at least…

Treatment with Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium (IMU-838) lowered the levels of a nerve damage marker in people with all subtypes of progressive multiple sclerosis (MS), including those without recent inflammatory activity. That’s according to an interim analysis of data from a Phase 2 study,…

Supplements of indole 3-lactate (ILA), a molecule made by gut bacteria, significantly reduced disease severity and promoted myelin repair in mouse models of multiple sclerosis (MS). That’s according to new findings presented by Larissa Jank, PhD, a postdoctoral researcher at Johns Hopkins University, at the Americas Committee for Treatment…

An association between the proteins IgG1 and CXCL10 in the fluid around the brain may help predict the risk of future disease activity for people in the early stages of multiple sclerosis (MS). That’s according to “CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker…

An imaging feature called the T1-dark rim, which is visible on standard MRI scans of people with multiple sclerosis (MS), could help to identify paramagnetic rim lesions (PRLs), a study suggests. PRLs are regions of chronic active inflammation that cause ongoing nerve damage. They’re associated with disease activity and…

Complement proteins, especially when activated in the brain and spinal cord, may contribute to nerve cell damage and more severe multiple sclerosis (MS) symptoms, a study that offers insights into a possible therapeutic target suggests. The study, “Complement Activation Is Associated With Disease Severity in Multiple Sclerosis,” was…

Treatment options for progressive types of multiple sclerosis (MS) have expanded dramatically over the past decade, and several promising experimental therapies are in late stages of clinical development, a new review paper highlights. The study, “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and…

The presence in the brain of chronic inflammatory lesions — called paramagnetic rim lesions (PRLs) — in people with multiple sclerosis (MS) is associated with a greater relapse burden and faster disability progression in the long term, according to a new U.S. study. Among more than 150 patients who…

An international team of scientists has created a computational model that seeks to give a picture of multiple sclerosis (MS) at multiple biological scales, from tiny molecules to whole cells to organs and its effects on the body overall. “In this study we have…

Use of oral ibudilast — being explored as a treatment for progressive forms of multiple sclerosis (MS) — was found to significantly slow the growth of chronic active lesions in the brains of patients with the neurodegenerative disease, according to MRI data from the SPRINT-MS study. Such lesions…

People with multiple sclerosis (MS) who received a university-level education are more likely to be on disease-modifying treatment (DMT) in regions with a publicly funded healthcare system, a U.K.-based study suggests. Advanced education was also linked to treatment starting faster and high-efficacy…

People in the early stages of multiple sclerosis (MS) who have more spontaneous myelin repair in the cortex — the outermost layer of the brain that’s critical for higher cognitive abilities — are less likely to experience worsening disability, a new analysis suggests. These findings have important implications for…

Gender and age at the onset of disease don’t seem to have a clinically relevant impact on disability progression in people with primary progressive multiple sclerosis (PPMS), according to a recent study in Argentina. Disease progression, based on the Expanded Disability Status…

New guidelines from the Spanish Society of Neurology emphasize the importance of early diagnosis and prompt treatment in the management of people with multiple sclerosis (MS). These guidelines also highlight a need to move beyond traditional views of “first line” and “second line” MS treatments, suggesting instead a…